Department of Biology and Genetics, Medical University of Gdańsk, Debinki 1, 80-210 Gdańsk, Poland.
J Appl Genet. 2010;51(1):95-106. doi: 10.1007/BF03195716.
Autosomal dominant hypercholesterolemia (ADH) is caused by mutations in the genes coding for the low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9). In this study, a molecular analysis of LDLR and APOB was performed in a group of 378 unrelated ADH patients, to explore the mutation spectrum that causes hypercholesterolemia in Poland. All patients were clinically diagnosed with ADH according to a uniform protocol and internationally accepted WHO criteria. Mutational analysis included all exons, exon-intron boundaries and the promoter sequence of the LDLR, and a fragment of exon 26 of APOB. Additionally, the MLPA technique was applied to detect rearrangements within LDLR. In total, 100 sequence variations were identified in 234 (62%) patients. Within LDLR, 40 novel and 59 previously described sequence variations were detected. Of the 99 LDLR sequence variations, 71 may be pathogenic mutations. The most frequent LDLR alteration was a point mutation p.G592E detected in 38 (10%) patients, followed by duplication of exons 4-8 found in 16 individuals (4.2%). Twenty-five cases (6.6%) demonstrated the p.R3527Q mutation of APOB. Our findings imply that major rearrangements of the LDLR gene as well as 2 point mutations (p.G592E in LDLR and p.R3527Q in APOB) are frequent causes of ADH in Poland. However, the heterogeneity of LDLR mutations detected in the studied group confirms the requirement for complex molecular studies of Polish ADH patients.
常染色体显性遗传性高胆固醇血症(ADH)是由编码低密度脂蛋白受体(LDLR)、载脂蛋白 B-100(APOB)或前蛋白转化酶枯草溶菌素/柯萨奇蛋白酶 9(PCSK9)的基因突变引起的。在这项研究中,对 378 名无血缘关系的 ADH 患者进行了 LDLR 和 APOB 的分子分析,以探索导致波兰高胆固醇血症的突变谱。所有患者均根据统一方案和国际公认的世卫组织标准临床诊断为 ADH。突变分析包括 LDLR 的所有外显子、外显子-内含子边界和启动子序列,以及 APOB 外显子 26 的一个片段。此外,还应用 MLPA 技术检测 LDLR 内的重排。共在 234 名(62%)患者中发现了 100 种序列变异。在 LDLR 中,检测到 40 种新的和 59 种以前描述过的序列变异。在 99 种 LDLR 序列变异中,71 种可能是致病性突变。最常见的 LDLR 改变是在 38 名(10%)患者中检测到的点突变 p.G592E,其次是在 16 名个体(4.2%)中发现的外显子 4-8 的重复。25 例(6.6%)表现出 APOB 的 p.R3527Q 突变。我们的研究结果表明,LDLR 基因的主要重排以及 2 种点突变(LDLR 中的 p.G592E 和 APOB 中的 p.R3527Q)是波兰 ADH 的常见原因。然而,在所研究的患者群体中检测到的 LDLR 突变的异质性证实了对波兰 ADH 患者进行复杂分子研究的必要性。